Replimune Group, Inc. (REPL)
AI stock analysis · as of Jul 29, 2026
Loading microstructure…
Replimune is a clinical-stage oncolytic immunotherapy company whose entire equity value hinges on the FDA's August 2, 2026 decision on RP1 for advanced melanoma — its third BLA attempt after two Complete Response Letters. With $0 product revenue, a $285M annual cash burn against only $209M cash, and FDA briefing documents just before the AdCom calling the pivotal IGNYTE data 'not interpretable,' the core question is binary: does RP1 get approved, or does the company face restructuring and severe dilution?
valuationImpossible to value on conventional multiples (no revenue, negative EBITDA, negative FCF yield of -38%); P/B of 2.66 is a probability-weighted option on RP1 approval — expensive if you assign <30% approval odds, cheap if you assign >50%.
This analysis is from Jul 29, 2026. Want the latest on REPL, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Binary setup with asymmetric payoff: stock at $5.35 vs. analyst high target of $17 and 52-week high of $12.50 — approval could re-rate the equity multiples given a ~13,000 patient/year U.S. melanoma TAM
- · Short interest at 49.86% of float with 7.62 days to cover creates meaningful squeeze potential on any positive AdCom vote or approval surprise
- · Pipeline optionality beyond RP1 melanoma: RP2 in uveal melanoma (REVEAL Phase 2/3), plus strong ORR signals in CSCC (56.3%), MCC (100% naive), and transplant CSCC (34.6% via ARTACUS)
- · In-house 63,000 sq ft Framingham manufacturing facility de-risks commercial supply and reduces CMO dependency if approval comes
- · Institutional ownership at 95.4% suggests sophisticated holders have not fully capitulated; price-to-book of 2.66 is modest for a late-stage biotech with a live BLA
- · AdCom votes have historically surprised positive on unmet-need oncology indications even when FDA reviewers are skeptical
Bear case
- · FDA briefing documents released July 27-28 called IGNYTE trial data 'not interpretable' — this is the FDA's third negative signal after two CRLs (April 2026 CRL reversed September 2025 Type A meeting guidance)
- · Cash of $209M against FY26 net loss of $314M and FCF of -$285M implies <9 months of runway; debt/equity of 67x and reliance on ATM offerings guarantees severe dilution
- · 10-K explicitly warns a third rejection could force restructuring of the entire RPx portfolio; company already eliminated its commercial/sales staff after the second CRL
- · Cantor Fitzgerald downgrade on April 13, 2026 (post-second CRL) reflects sell-side skepticism; no upgrades in 90 days
- · IGNYTE-3 confirmatory Phase 3 design remains unresolved — FDA rescinded its own September 2025 comparator guidance, meaning even approval could come with an unworkable post-marketing burden
- · Emerging shareholder legal probe adds overhang; sentiment score of -0.82 reflects broad institutional loss of confidence
- · ROE of -108% and negative EV/EBITDA underscore the fundamental unsustainability absent approval
Catalysts
- · FDA Advisory Committee meeting late July 2026 — the immediate binary event; briefing docs already negative
- · FDA PDUFA action date August 2, 2026 — approval, CRL, or delay
- · Q1 FY27 earnings August 6, 2026 — cash runway update and management commentary on restructuring contingencies
- · Potential short squeeze on any positive AdCom vote given 49.9% short float and 7.6 days to cover
- · REVEAL Phase 2/3 transition expected Q1 2027 — provides pipeline optionality if RP1 fails
- · Any follow-on equity raise announcement — likely near-term given burn rate
Key risks
- · Third CRL on August 2, 2026 — would likely trigger company-wide restructuring and >50% additional downside
- · Massive equity dilution via ATM in the next 2-3 quarters regardless of FDA outcome
- · IGNYTE-3 confirmatory trial design impasse could invalidate an accelerated approval path even if granted
- · Debt covenant risk on the October 2022 term loan (amended January 2026) if cash falls further
- · Going concern language in future filings would trigger forced selling by institutional holders
What to watch
- · Late July 2026 AdCom vote — margin and tone of committee discussion
- · August 2, 2026 FDA action — approval, CRL, or extension
- · August 6, 2026 earnings — cash position, runway guidance, restructuring commentary
- · Any 8-K filings on ATM draws, term loan amendments, or going concern language
- · Short interest and borrow rate trends into AdCom — squeeze setup
- · Key technical levels: $1.50 (52-week low, bear floor) and $12.50 (52-week high, bull ceiling)
Key metrics
Price target rationale
Base case ($4) assumes ~30% approval probability weighted against a $12+ approval scenario and $1.50 rejection floor, adjusted for near-certain dilution. Bull case ($15) reflects AdCom positive vote + approval + short squeeze re-rating toward peak analyst target. Bear case ($1.50, matching 52-week low) assumes third CRL forces restructuring, dilutive raise, and pipeline wind-down.
On Wall Street's view (mixed): The $10.67 mean target predates the July 27-28 FDA briefing document release and likely overstates approval probability; the $2 low target better reflects the post-briefing-doc risk profile, so we sit between consensus and the bear-case analyst.
Latest filing (10-K)
Replimune's entire near-term survival hinges on the FDA's August 2, 2026 decision on its third RP1 BLA submission after two CRL rejections; approval unlocks a ~13,000-patient U.S. melanoma market, while a third rejection likely forces a company-wide restructuring.
Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies based on its proprietary RPx platform, which uses engineered HSV-1 viruses injected directly into tumors to kill cancer cells and stimulate systemic anti-tumor immune responses. The company has no approved products and generates no product revenue; it funds operations through equity offerings and a term loan facility. Its lead asset RP1 (vusolimogene oderparepvec) is under FDA BLA review for advanced melanoma in combination with BMS's nivolumab.
What the news says · bearish
The dominant storyline is a severe regulatory setback for Replimune's lead drug RP1, an oncolytic virus therapy for melanoma. FDA briefing documents released around July 27-28 flagged the trial data as 'not interpretable' and raised significant efficacy concerns, triggering a 28-32% stock collapse over two sessions. The situation is compounded by mounting financial losses and an emerging legal probe, suggesting institutional confidence has been badly shaken ahead of the advisory committee meeting. A brief mid-week pop on rumors of FDA leadership changes (Marty Makary firing) proved fleeting and was overwhelmed by the weight of the negative regulatory documents. Unless the advisory committee vote surprises to the upside, the near-term outlook remains deeply challenged.
This analysis is from Jul 29, 2026. Markets move. Get the current read on REPL and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.